Navigation Links
Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
Date:5/27/2009

-Clinical study planned for relapsed / refractory acute myelogenous leukemia-

PRINCETON, N.J., May 27 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1338, for the treatment of patients with acute myelogenous leukemia (AML). MDX-1338 is a fully human antibody that targets CXCR4, a chemokine receptor found on the surface of many cancer cells, including certain leukemias, lymphomas and other cancers. Preclinical laboratory experiments have shown that MDX-1338 can block the growth of, and even directly kill, selected human tumor cells.

The Phase 1, open-label, multicenter, dose-escalation study of MDX-1338 as a monotherapy and in combination with chemotherapy is expected to enroll up to 34 patients with relapsed/ refractory AML. This trial is designed to establish and evaluate the safety, tolerability and maximum tolerated dose, as well as preliminary pharmacodynamics and efficacy of MDX-1338.

"We are pleased that MDX-1338 has progressed into the clinic, representing our eighth development candidate in oncology and further enhancing our focus on oncology/immunology therapeutic indications," said Howard H. Pien, Chairman and CEO of Medarex. "We believe that MDX-1338 could have potential activity in multiple cancers. Our first Phase 1 study will be conducted in AML and future studies are expected to target a variety of other leukemias and solid tumors and may involve monotherapy and combination therapy."

The American Cancer Society estimates that in 2008, approximately 13,290 patients in the United States will be diagnosed with AML.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, developm
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
2. Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
3. Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
4. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
5. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
6. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
7. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
8. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
9. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
10. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
11. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a multivariate ... has appointed Holly B. Bauzon as Vice ... Bauzon has a proven track record in both increasing ... companies. She has more than 20 years of healthcare ... the position of Director, Lab Services Sales and Managed ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is ... introduction of the first-of-its-kind comic book available in ... has been designed specifically to educate children and their parents ... Canada affecting more than 300,000 Canadians. Eisai is ... care (hhc) , in which the patient is central – ...
(Date:8/21/2014)... MISSION, Kan. , Aug. 21, 2014 /PRNewswire-iReach/ ... Information Trust Alliance (HITRUST) under its Common Security ... ScriptPro,s Enterprise Security and Privacy Manager, "We appreciate ... the level of commitment that this certification signifies. ... compliant." ABOUT THE CSF CERTIFICATION PROCESS: ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2ScriptPro Achieves HITRUST Certification 2
(Date:8/21/2014)... Albany, Ohio (PRWEB) August 21, 2014 ... that he took his own life by hanging, likely ... Sharry Edwards, the foremost BioAcoustic Vocal Profiling ... show offering novel information concerning Williams’ death; hoping to ... Several issues relevant to Williams’ suicide were proposed ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The costs paid ... continue to rise, according to insurer data. The Quotes Pros ... in real time using its tools at http://quotespros.com . ... the company homepage connects with providers offering multiple coverage packages ... are promoted to the public are now easier to compare ...
(Date:8/21/2014)... Today, Zane Benefits, the #1 Online Health ... credits in 2015. , According to Zane Benefits, premium ... Affordable Care Act (ACA), premium tax credits are available ... through the Health Insurance Marketplaces. , The new article ... of the tax credits, updated for 2015. , ...
(Date:8/21/2014)... chronic kidney disease patients may be a strong indicator ... in the Journal of the American Society of ... Hopkins Bloomberg School of Public Health assert that coronary ... atherosclerosis in predicting the risk of heart disease among ... all patients with chronic kidney disease (CKD) die from ...
(Date:8/21/2014)... Texas MD Anderson Cancer Center today announced a new ... screening at a network of community breast care centers ... November, MD Anderson will become the exclusive provider of ... 10 breast care centers, located in Memorial City, The ... the network will expand to Memorial Hermann,s locations in ...
Breaking Medicine News(10 mins):Health News:Robin Williams: What he could not bear to face 2Health News:Robin Williams: What he could not bear to face 3Health News:Dental Insurance Now Quoted for Families Online at Insurer Portal 2Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:MD Anderson and Memorial Hermann to operate breast screening network across Houston area 2
... of Pittsburgh in USA, charged with causing involuntary manslaughter of ... gone to a bar, leaving the children unattended. ... "God Loves You More," Shakita Mangham, 25, arrived at municipal ... headquarters a short time later. They are being charged with ...
... Researchers have designed a pair of new vaccines that not ... withdrawal symptoms. ,The study was conducted by ... Jay H. Waggoner at Baylor College of Medicine (BCM). ... of the vaccines on subjects administered to it. ...
... decline, thanks to the comprehensive program in 2002, encouraging smokers ... report shows a decline in the smoking rate by 20%, ... smoking decreased among men (from 22.5% to 19.9%) and among ... year-long ad campaign aimed at prompting more smokers to quit. ...
... count up to ten, identified colours and even dabbled with ... IQ test that her soaring brainpower was established. ... the youngest female celebrated member of Mensa. ,The youngest ... been described by Britain's leading expert on intelligent children as ...
... Grunenthal GmbH presented the first clinical evidence for ... release) for patients suffering from chronic pain ... Against Rheumatism (EULAR), 13-16 June 2007, Barcelona, Spain. ... of its kind, combining two analgesic principles, mu-receptor ...
... new modified drug for Alzheimers disease.The drug has begun ... of people suffer from this devastating disease and treatment options ... led the creation of the treatment molecule. "Current drugs manage ... It may be able to prevent and reverse the disease." ...
Cached Medicine News:Health News:Mothers of Children Killed in Fire Charged With Manslaughter 2Health News:Mothers of Children Killed in Fire Charged With Manslaughter 3Health News:New York Records Decline in Smoking Rate 2Health News:Two-year-old Joins Mensa, Becomes Its Youngest Ever Genius 2Health News:Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment 2Health News:Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment 3Health News:Modified Drug Therapy for Alzheimers Disease 2
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
Inquire...
250L...
250L...
Medicine Products: